Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy.
Rituximab, a monoclonal antibody against B-cell membrane marker CD-20, is an effective treatment for immunoglobulin M (IgM) monoclonal anti-myelin-associated glycoprotein (MAG) neuropathies. We report a patient with an autonomic and painful sensory neuropathy associated with an IgM lambda monoclonal gammopathy, responsive to rituximab. Treatment resulted in a decline in total IgM and improvement in the patient's painful neuropathy and dysautonomia. Rituximab may be an effective and tolerable treatment for autonomic and sensory neuropathy associated with IgM monoclonal gammopathy.
Goldfarb
Adina R
AR
Peripheral Neuropathy Center, Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 635 Madison Avenue, Suite 400, New York, New York 10022, USA.
Weimer
Louis H
LH
Brannagan
Thomas H
TH
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001342:Autonomic Nervous System Diseases / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy*; D005260:Female; D006801:Humans; D007075:Immunoglobulin M; D010265:Paraproteinemias / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D000069283:Rituximab